Century Therapeutics (NASDAQ:IPSC) Trading Up 2.5% – Time to Buy?

Century Therapeutics, Inc. (NASDAQ:IPSC)’s stock price shot up 2.5% during trading on Monday . The stock traded as high as $0.5860 and last traded at $0.5719. 655,586 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 885,292 shares. The stock had previously closed at $0.5577.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 target price (down from $7.00) on shares of Century Therapeutics in a report on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 20th. Finally, Leerink Partnrs cut Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Century Therapeutics currently has an average rating of “Hold” and an average price target of $3.40.

Century Therapeutics Stock Up 2.5%

The company has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.55. The company has a market cap of $49.98 million, a price-to-earnings ratio of -1.79 and a beta of 1.80.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. On average, research analysts predict that Century Therapeutics, Inc. will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Century Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC lifted its holdings in Century Therapeutics by 64.1% in the 3rd quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock valued at $180,000 after acquiring an additional 140,891 shares during the last quarter. Two Sigma Investments LP lifted its stake in Century Therapeutics by 59.2% during the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after purchasing an additional 338,902 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Century Therapeutics by 483.1% during the third quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock worth $118,000 after buying an additional 195,573 shares in the last quarter. GSA Capital Partners LLP grew its position in Century Therapeutics by 29.3% in the third quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock worth $301,000 after buying an additional 136,873 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Century Therapeutics in the second quarter valued at $248,000. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.